CD34(+) immunoselected cells for poor graft function following allogeneic BMT.

BACKGROUND Poor graft function without signs of graft rejection following allogeneic BMT (allo-BMT) occurs in around 9% of patients. A high incidence of hazardous complications may be encountered, leading to life-threatening situations. METHODS We describe three patients who underwent allo-BMT for acute leukemia in first complete remission and untreated myelodysplastic syndrome. The three patients experienced prolonged and profound granulocytopenia, anemia and thrombocytopenia, despite growth factors and transfusions. This was not corrected by donor leukocytes infusion. They received a boost of CD34(+) positively-selected cells from their HLA-identical sibling donors. RESULTS A rapid improvement of peripheral blood cell counts was observed in both patients who were in full donor chimerism status at time of boost infusion, whereas the patient with mixed chimerism did not show any signs of improvement. Neither patient suffered further exacerbation of GvHD. DISCUSSION Allogeneic positively-immunoselected CD34(+) cells can represent an interesting alternative treatment for poor graft function following allo-BMT, in the absence of graft rejection signs.

[1]  L. Kanz,et al.  Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. , 1996, Bone marrow transplantation.

[2]  L. Arseniev,et al.  Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor. , 1994, Bone marrow transplantation.

[3]  H. Lazarus,et al.  Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation. , 1994, Blood reviews.

[4]  M. Cazzola,et al.  Accelerated erythroid repopulation with no stem‐cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation , 1993, British journal of haematology.

[5]  N. Schmitz,et al.  Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation [letter] , 1993 .

[6]  R. M. Fox,et al.  Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy , 1992, The Lancet.

[7]  J. Armitage,et al.  The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies. , 1991, Bone marrow transplantation.

[8]  J. Singer,et al.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. , 1990, Blood.